Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine
| Autor: | Gilles Peytavin, Sinata Koulla-Shiro, Maguy Njoume, Alexandra Calmy, Charles Kouanfack, Laurence Vergne, Charlotte Brulet, Eric Delaporte, Laura Ciaffi, Yvette Mawamba Nkene, Eitel Mpoudi-Ngole, Christian Laurent |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Nevirapine Anti-HIV Agents Immunology Fixed-dose combination Acquired immunodeficiency syndrome (AIDS) Drug Resistance Viral medicine Immunology and Allergy Humans Sida biology Reverse-transcriptase inhibitor Stavudine Lamivudine Viral Load biology.organism_classification medicine.disease Virology Long-Term Care CD4 Lymphocyte Count Infectious Diseases Treatment Outcome Reverse Transcriptase Inhibitors Drug Therapy Combination Female Long term safety medicine.drug |
| Zdroj: | AIDS (London, England). 21(6) |
| ISSN: | 0269-9370 |
| Popis: | We assessed the long-term safety, effectiveness and quality of a fixed-dose combination of nevirapine, stavudine and lamivudine (triomune). HIV-1-infected adults initially enrolled in a one-year, open-label, single-arm, multicentre trial in Cameroon were followed for 2 years. Our results support the safety and effectiveness of the triomune combination for first-line treatment of HIV infection. Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|